Actinogen Medical Ltd (ACW)

Snapshot

ACW's Principal Activity is the development of Xanamem, a novel treatment for Alzheimer's disease and the cognitive deficiency associated with other neurological and metabolic diseases.

Announcements

Corporate Overview

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date	Amount	Franking	Gross	Type	Payable
No dividends paid.

Show All

See Upcoming Dividends for all ASX companies.

Directors & Management

Name	Title	Since	Bio
Dr Steven Gourlay	Chief Executive Officer,Managing Director	Mar 2021	Dr Steven Gourlay Chief Executive Officer,Managing Director Dr Gourlay has more than 30 years of experience in the development of novel therapeutics. Formerly the founding Chief Medical Officer (CMO) at US-based Principia Biopharma Inc., Dr Gourlay was responsible for the supervision of multiple pre-clinical, first-in-human, Phase 2 and 3 clinical trial programs for four small molecules in orphan immunological diseases, multiple sclerosis and cancer. The data generated by these trials, and Dr Gourlay's roadshow presentations, supported a NASDAQ IPO of Principia Biopharma Inc. in 2018 - subsequently followed by an acquisition of by Sanofi in 2020. Prior to Principia Biopharma, Dr Gourlay was a Partner at GBS Venture Partners, the Australian specialist life sciences and healthcare venture capital firm, where he was involved in the development and exit of multiple clinical stage therapeutic companies including Elastagen, Spinifex and Peplin. Before GBS, and after a postdoc in clinical pharmacology at the University of California San Francisco, he held positions of increasing responsibility at Genentech, Inc. in the areas of pharmacoepidemiology and early clinical development. Dr Gourlay has drug regulatory experience with the US Food and Drug Administration (FDA), European Medicines Agency (EMA) at many levels, including filing more than 10 Investigational New Drug (IND) applications, achieving several orphan drug status approvals for his Company's product(s), and completing several biologics license applications. Dr Gourlay has been acting as a consultant CMO to Actinogen since December 2020.
Dr Geoffrey E.D Brooke	Non-Executive Chairman,Non-Executive Director	Feb 2021	Dr Geoffrey E.D Brooke Non-Executive Chairman,Non-Executive Director Dr Brooke is a healthcare industry and venture capital veteran with over 30 years' international experience as the founder, lead investor and/or Chairman/Director of numerous healthcare companies. He was the Managing Director and Founder of leading life sciences venture capital firm, GBS Ventures. There, Dr Brooke was responsible for GBS's healthcare venture activity in the region. Dr Brooke was also responsible for numerous investments and exits via NASDAQ and ASX public listings and trade sales, as well as being lead investor in numerous investments syndicated in multiple rounds with premier US venture firms. Dr Brooke was also President and Founder of US-based seed healthcare venture capital firm, Medvest Inc., with investors including the venture capital arm of global multinational medical devices, pharmaceutical and consumer packaged goods manufacturer, Johnson & Johnson. Dr Brooke now acts as a private investor in, and independent director for, a number of small to medium-sized Australian and US private and public companies.
Mr Malcolm John McComas	Non-Executive Director	Apr 2019	Mr Malcolm John McComas Non-Executive Director Mr McComas has over 25 years of experience in the financial services industry with experience in corporate finance, mergers and acquisitions, debt and equity funding transactions across multiple industry sectors. He held senior leadership roles with Grant Samuel, County NatWest (now Citigroup) and Morgan Grenfell (now Deutsche Bank) in Australia and the UK. Prior to this Mr McComas was a lawyer at Herbert Geer specialising in tax. Mr McComas is an experienced company director and currently services number of listed entities, and also has not-for-profit involvement as a director of the Australasian Leukemia and Lymphoma Group.
Dr George Morstyn	Non-Executive Director	Dec 2017	Dr George Morstyn Non-Executive Director Dr Morstyn has more than 25 years; experience in the biotechnology industry including as Senior Vice President of Development and Chief Medical Officer at Amgen Inc. Dr Morstyn had responsibility globally for drug development in all therapeutic areas including neuroscience at Amgen Inc. and was a member of the Operating Committee. Many new products were approved and launched during Dr Morstyn's tenure. Prior to joining Amgen Inc. Dr Morstyn has been a Non-Executive Director of various for-profit and not-for-profit companies, including many biotechnology companies. He is currently on the Board of the Cooperative Research Centre for Cancer Therapeutics, Symbio (Tokyo) and Biomedical Research Victoria.
Mr Peter Webse	Company Secretary	N/A

Show All

Director Transactions

Date	Director	Type	Amount	Price	Value	Notes
17/11/20	Malcolm McComas	Issued	100,000	$0.022	$2,200	Rights issue
17/11/20	George Morstyn	Issued	40,000	$0.022	$880	Rights issue
17/11/20	John (Bill) Ketelbey	Issued	1,862,182	$0.022	$40,968	Rights issue
17/11/20	John (Bill) Ketelbey	Issued	128,579	$0.022	$2,828	Rights issue
17/11/20	Geoffrey Brooke	Issued	265,000	$0.022	$5,830	Rights issue
31/01/20	John (Bill) Ketelbey	Cancelled	3,000,000	$0.035	$105,000	Cancellation of securities
22/11/19	John (Bill) Ketelbey	Transfer	9,000,000	$0.05	$450,000	As advised by the company
22/11/19	John (Bill) Ketelbey	Transfer	9,000,000	$0.05	$450,000	As advised by the company
12/04/19	Malcolm McComas	Issued	3,000,000	$0.052	$156,000	Issue of options
13/12/18	Geoffrey Brooke	Issued	4,900,000	$0.048	$235,200	Issue of options
13/12/18	John (Bill) Ketelbey	Issued	11,700,000	$0.048	$561,600	Issue of options

Show All

Director Interests

Director	Last Notice	Direct Shares	Indirect Shares	Options	Convertibles
Steven Gourlay	24/03/2021	N/A	63,362,300	N/A	N/A
Geoffrey Brooke	17/11/2020	0	1,590,000	9,900,000	N/A
Malcolm McComas	17/11/2020	N/A	600,000	3,000,000	N/A
George Morstyn	17/11/2020	N/A	240,000	3,000,000	N/A

Show All

Top 20 Shareholders

About the Data

Name	Shares	Capital
HSBC Custody Nominees (Australia) Limited	227,303,623	20.36%
Edinburgh Technology Fund Limited	48,147,864	4.31%
Surfit Capital Pty Ltd	30,000,000	2.69%
Tisia Nominees Pty Ltd (Henderson Family A/C)	27,867,184	2.50%
Mrs Sarah Cameron	25,916,573	2.32%
Brazil Farming Pty Ltd	15,000,000	1.34%
Citicorp Nominees Pty Ltd	10,604,474	0.95%
Mr Steven Veronese	10,008,001	0.90%
Oaktone Nominees Pty Ltd (Grist Investment A/C)	10,000,000	0.90%
Mrs Gillian Karen Nes & Mrs Ronald Nes (Giro S/F A/C)	9,950,000	0.89%
Kaleidoscope Holdings Pty Ltd (Kaleidoscope Super A/C)	9,000,000	0.81%
Griffin & Grace Investments Pty Ltd (Griffin & Grace Inv S/F A/C)	8,800,000	0.79%
Mr Peter James Nixon	8,400,000	0.75%
Alua Capital Pty Ltd	8,000,000	0.72%
BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd Drp	7,738,901	0.69%
BNP Parabis Nominees Pty Ltd (Bnpp Nyb Clearing Acc Drp)	7,560,729	0.68%
Bannaby Investments Pty Ltd (Super Fund A/C)	7,500,000	0.67%
Webinvest Pty Ltd (Olsb Unit A/C)	7,000,000	0.63%
Romfal Sifat Pty Ltd (The Fizmail Family A/C)	7,000,000	0.63%
Paranji Super Fund Pty Ltd (Paranji Superfund A/C)	6,500,000	0.58%

Show All

Shareholder Distribution

As reported in the most recent Annual Report.

The most recent Annual Report didn't contain Shareholder Distribution data.

Substantial Shareholders

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Share Price History

Date	Close	Change	%Chg	Open	High	Low	Volume	Turnover

Full Month

Historical Data

Year	Closing Price	Last Trade
2020	$0.022	30 June
2019	$0.01	28 June
2018	$0.048	29 June
2017	$0.061	28 June
2016	$0.072	28 June
2015	$0.072	30 June
2014	$0.011	30 June

ACW Historical Price Data (CSV)

Up to 20 years of EOD share price history

Sign up to Download

You must be logged in to access this feature. Please sign up for free or login.